Codelivery of curcumin and doxorubicin by MPEG-PCL results in improved efficacy of systemically administered chemotherapy in mice with lung cancer

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 3521-3531

  Wang, Bi Lan ^a   Shen, Yong Mei ^a,b   Zhang, Qiong Wen ^a   Li, Yu Li ^a   Luo, Min ^a   Liu, Ze ^a   Li, Yan ^a   Qian, Zhi Yong ^a   Gao, Xiang ^a   Shi, Hua Shan ^a  

^a SICHUAN UNIVERSITY   (China)

^b Sichuang Haoyisheng Pharmacy   (China)

Author keywords

Cancer; Curcumin; Doxorubicin; Methoxy poly(ethylene glycol); Micelles; Poly(caprolactone); Treatment

Indexed keywords

COPOLYMER; CURCUMIN; DOXORUBICIN; METHOXY POLY(ETHYLENE GLYCOL) POLY(CAPROLACTONE) COPOLYMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; EMBRYO; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MICELLIZATION; MOUSE; NONHUMAN; TUMOR CELL;

CANCER; CURCUMIN; DOXORUBICIN; METHOXY POLY(ETHYLENE GLYCOL); MICELLES; POLY(CAPROLACTONE); TREATMENT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CURCUMIN; DOXORUBICIN; FEMALE; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MICELLES; NANOCAPSULES; PARTICLE SIZE; POLYESTERS; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 84884548821     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S45250     Document Type: Article

References (45)

1. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloyl-methane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood. 2003;101:1053-1062.
2. Jobin C, Bradham CA, Russo MP, et al. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol. 1999;163:3474-3483.
3. Kunnumakkara AB, Diagaradjane P, Guha S, et al. Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin Cancer Res. 2008;14:2128-2136.
4. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an old-age disease with an age-old solution. Cancer Lett. 2008;267:133-164.
5. Duvoix A, Blasius R, Delhalle S, et al. Chemopreventive and therapeutic effects of curcumin. Cancer Lett. 2005;223:181-190.
6. Mitchell TM. Correspondence re: Somasundaram et al. Dietary cur-cumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res. 2002;62:3868-3875.
7. Somasundaram S, Edmund NA, Moore DT, Small GW, Shi YY, Orlowski RZ. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res. 2002;62: 3868-3875.
8. van't Land B, Blijlevens NM, Marteijn J, et al. Role of curcumin and the inhibition of NF-kappaB in the onset of chemotherapy-induced mucosal barrier injury. Leukemia. 2004:18:276-284.
9. Du B, Jiang L, Xia Q, Zhong L. Synergistic inhibitory effects of cur-cumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29. Chemotherapy. 2006;52:23-28.
10. Patel BB, Sengupta R, Qazi S, et al. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer. 2008;122: 267-273.
11. Chen YR, Tan TH. Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene. 1998;17:173-178.
12. Arbiser JL, Klauber N, Rohan R, et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med. 1998;4:376-383.
13. Lin YG, Kunnumakkara AB, Nair A, et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res. 2007;13:3423-3430.
14. Dorai T, Cao YC, Dorai B, Buttyan R, Katz AE. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate. 2001;47:293-303.
15. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits pro-liferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 2008;269:199-225.
16. Bhaumik S, Anjum R, Rangaraj N, Pardhasaradhi BV, Khar A. Curcumin mediated apoptosis in AK-5 tumor cells involves the production of reactive oxygen intermediates. FEBS Lett. 1999;456:311-314.
17. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates expres-sion of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol. 2006;69:195-206.
18. Menon LG, Kuttan R, Kuttan G. Anti-metastatic activity of curcumin and catechin. Cancer Lett. 1999;141:159-165.
19. Bisht S, Feldmann G, Soni S, et al. Polymeric nanoparticle-encapsulated curcumin (nanocurcumin): a novel strategy for human cancer therapy. J Nanobiotechnology. 2007;5:3.
20. Lao CD, Ruffin MT IV, Normolle D, et al. Dose escalation of a cur-cuminoid formulation. BMC Complement Altern Med. 2006;6:10.
21. Bisht K, Wagner KH, Bulmer AC. Curcumin, resveratrol and flavonoids as anti-inflammatory, cyto- and DNA-protective dietary compounds. Toxicology. 2010;278:88-100.
22. Shahani K, Swaminathan SK, Freeman D, Blum A, Ma L, Panyam J. Injectable sustained release microparticles of curcumin: a new concept for cancer chemoprevention. Cancer Res. 2010;70:4443-4452.
23. Shutava TG, Balkundi SS, Vangala P, et al. Layer-by-layer-coated gelatin nanoparticles as a vehicle for delivery of natural polyphenols. ACS Nano. 2009;3:1877-1885.
24. Shieh YA, Yang SJ, Wei MF, Shieh MJ. Aptamer-based tumor-targeted drug delivery for photodynamic therapy. ACS Nano. 2010;4: 1433-1442.
25. Wang T, He N. Preparation, characterization and applications of low-molecular-weight alginate-oligochitosan nanocapsules. Nanoscale. 2010;2:230-239.
26. He N, Wang T, Jiang L, Wang D, Hu Y, Zhang L. Therapy for cerebral ischemic injury with erythropoietin-containing nanoparticles. J Nanosci Nanotechnol. 2010;10:5320-5323.
27. Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin. 2008;58:97-110.
28. Wei X, Gong C, Gou M, et al. Biodegradable poly(epsilon-caprolactone)- poly(ethylene glycol) copolymers as drug delivery system. Int J Pharm. 2009;381:1-18.
29. Gou M, Wei X, Men K, et al. PCL/PEG copolymeric nanoparticles: potential nanoplatforms for anticancer agent delivery. Curr Drug Targets. 2011;12:1131-1150.
30. Shi HS, Gao X, Li D, et al. A systemic administration of liposomal curcumin inhibits radiation pneumonitis and sensitizes lung carcinoma to radiation. Int J Nanomedicine. 2012;7:2601-2611.
31. Safavy A, Raisch KP, Mantena S, et al. Design and development of water-soluble curcumin conjugates as potential anticancer agents. J Med Chem. 2007;50:6284-6288.
32. Guo G, Fu S, Zhou L, et al. Preparation of curcumin loaded poly(ε-caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone) nanofibers and their in vitro antitumor activity against glioma 9L cells. Nanoscale. 2011;3:3825-3832.
33. Men K, Gou ML, Guo QF, et al. A novel drug and gene co-delivery system based on poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) grafted polyethyleneimine micelle. J Nanosci Nanotechnol. 2010;10:7958-7964.
34. Gou M, Zheng X, Men K, et al. Self-assembled hydrophobic honokiol loaded MPEG-PCL diblock copolymer micelles. Pharm Res. 2009;26:2164-2173.
35. Shi HS, Li D, Zhang J, et al. Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice. Cancer Sci. 2010;101:1447-1453.
36. Lopes de Menezes DE, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 1998;58:3320-3330.
37. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
38. Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc. 2008;83:355-367.
39. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136:260-271.
40. Yanagawa H, Bando H, Takishita Y. Dose-intensive chemotherapy with cisplatin, vincristine, doxorubicin and etoposide against lung cancer: a pilot study. Anticancer Res. 1995;15:613-616.
41. Di Santo R, Costi R, Artico M, et al. Design, synthesis and biologi-cal evaluation of heteroaryl diketohexenoic and diketobutanoic acids as HIV-1 integrase inhibitors endowed with antiretroviral activity. Farmaco. 2005;60:409-417.
42. Abouzid KA, Khalil NA, Ahmed EM, Zaitone SA. Synthesis and biological evaluation of new heteroaryl carboxylic acid derivatives as anti-inflammatory-analgesic agents. Chem Pharm Bull (Tokyo). 2013;61:222-228.
43. Xu Y, Ku B, Tie L, et al. Curcumin reverses the effects of chronic stress on behavior, the HPA axis, BDNF expression and phosphorylation of CREB. Brain Res. 2006;1122:56-64.
44. Shi M, Cai Q, Yao L, Mao Y, Ming Y, Ouyang G. Antiproliferation and apoptosis induced by curcumin in human ovarian cancer cells. Cell Biol Int. 2006;30:221-226.
45. Sen GS, Mohanty S, Hossain DM, et al. Curcumin enhances the efficacy of chemotherapy by tailoring p65NFκB-p300 cross-talk in favor of p53-p300 in breast cancer. J Biol Chem. 2011;286:42232-42247.